**Diabetic Nephropathy: Role of Aldosterone and Benefits of Therapy with Aldosterone Receptor Blocker**

Jayson Yap and Mohammad G. Saklayen *VA Medical Center and Wright State University Boonshoft School of Medicine, Dayton, OH USA* 

#### **1. Introduction**

40 Diabetic Nephropathy

[30] Reich HN, Oudit GY, Penninger JM, Scholey JW, Herzenberg AM. Decreased

[31] Shiota A, Yamamoto K, Ohishi M, Tatara Y, Ohnishi M, Maekawa Y, Iwamoto Y,

[32] Zhang SL, To C, Chen X, Filep JG, Tang SS, Ingelfinger JR, Chan JSD. Essential role(s) of

[33] Giacco F, Brownlee M. Oxidative stress and diabetic complications. *Circ Res.* 2010; 107:

[34] Sachetelli S, Liu Q, Zhang SL, Liu F, Hsieh TJ, Brezniceanu ML, Guo DF, Filep JG,

[35] Ding Y, Davisson RL, Hardy DO, Zhu LJ, Merrill DC, Catterall JF, Sigmund CD. The

[37] Godin N, Liu F, Lau GJ, Brezniceanu ML, Chénier I, Filep JG, Ingelfinger JR, Zhang SL,

[38] Brezniceanu ML, Liu F, Wei C-C, Chénier I, Godin N, Zhang SL, Filep JG, Ingelfinger

[39] Brezniceanu ML, Lau CJ, Godin N, Chénier I, Duclos A, Ethier J, Filep JG, Ingelfinger

angiotensinogen transgenic mice. *Kidney Int*. 2010; 77:1086-1097.

angiotensin 1-9. Circ Res. 2000; 87:E1-9.

2010; 33:298-307.

1058-1070.

kidney disease. *Kidney Int.* 2008; 74: 1610–6.

high glucose. J Am Soc Nephrol. 2002; 13:302-12.

gene in the kidney. *Kidney Int.* 2006; 69:1016-1023.

*Exp Nephrol.* 2006; 105: 45-52.

2008; 57:451-459

converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to

glomerular and tubular expression of ACE2 in patients with type 2 diabetes and

Takeda M, Rakugi H. Loss of ACE2 accelerates time-dependent glomerular and tubulointerstitial damage in streptozotocin-induced diabetic mice. *Hypertens Res.*

the intrarenal renin-angiotensin system in transforming growth factor-beta1 gene expression and induction of hypertrophy of rat kidney proximal tubular cells in

Ingelfinger JR, Sigmund CD, Hamet P, Chan JSD. RAS blockade decreases blood pressure and proteinuria in transgenic mice overexpressing rat angiotensinogen

kidney androgen-regulated protein promoter confers renal proximal tubule cellspecific and highly androgen-responsive expression on the human angiotensinogen gene in transgenic mice. *J Biol Chem*. 1997; 272: 28142-28148. [36] Sugaru E, Nakagawa T, Ono-Kishino M, Nagamine J, Tikunaga T, Kitoh M, Hume WE,

Nagata R, Taiji M: Amelioration of established diabetic nephropathy by combined treatment with SMP-534 (antifibrotic agent) and losartan in db/db mice. *Nephron* 

Chan JSD. Catalase overexpression prevents hypertension and tubular apoptosis in

JR, Chan JSD. Attenuation of interstitial fibrosis and tubular apoptosis in db/db transgenic mice overexpressing catalase in renal proximal tubular cells. *Diabetes* 

JR, Zhang SL, Chan JSD. Reactive oxygen species promote caspase-12 expression and tubular apoptosis in diabetic nephropathy. *J Am Soc Nephrol*. 2010; 21:943-954.

ACE-inhibitor and angiotensin receptor blocker (ARB) have been shown to reduce proteinuria and progression of renal dysfunction in both type 1 and type 2 diabetics (1-11). However, even with optimal use of ACE-Inhibitor or ARB, the progression of renal dysfunction is not completely stopped. Even in studies where ACEI or ARB therapy showed improved outcome, a very high percentage of patients still progress. This scenario is now highlighted in a recent study published in JAMA, which shows the incidence of diabetic nephropathy increasing in USA in excess of what can be accounted for by the increased incidence of type 2 DM in the population (12). The present treatment strategy is therefore not adequate and other additional effective treatment strategies are urgently needed.

Since the publication of the landmark RALES study (13) showing a significant survival benefit in patients with systolic heart failure when treated with aldosterone inhibition in addition to ACEI and beta-blockers, the interest in the vasculotoxic effect of aldosterone and the beneficial therapeutic effects of aldosterone receptor blocker drugs like spironolactone has been steadily increasing (14).

#### **2. Aldosterone biology and lessons learnt from animal models**

In addition to its classical action in the distal nephron, aldosterone is now known to exert many other effects on other areas of kidneys as well as in cardiovascular tissues. (14 )

Aldosterone is now known to have a significant role in renal hemodynamics, independent of Angiotensin II. In a remnant kidney model in the rat Greene et al showed that there was >10-fold rise in aldosterone in the remnant kidney rats (REM) compared to sham operated ones (15). As expected, proteinuria, hypertension and glomerulosclerosis in the REM rats were attenuated with treatment using ACE-inhibitor or angiotensin receptor blockers. However, when these treated rats (REM AIIA) were given an aldosterone infusion the extent of proteinuria, hypertension and glomerulosclerosis were similar to untreated (REM) rats, suggesting deleterious renal hemodynamic effects of aldosterone independent of angiotensin II. Use of spironolactone in these rats transiently reduced proteinuria and lowered arterial pressure.

Diabetic Nephropathy: Role of Aldosterone and

octadecenoic acid, *SMC* smooth muscle cell

sugar or blood pressure (33).

Benefits of Therapy with Aldosterone Receptor Blocker 43

renal injury scores and decreased (pro)renin receptor protein expression, angiotensinogen

and AT1R mRNA levels and kidney Ang II content in the same rat model. (32)

Fig. 1. Angiotensin-Aldosterone Axis and the Physiologic Effects of Aldosterone *ROS* Reactive Oxygen Species, *AT1* Angiotensin I, *EKODE* epoxy-9keto-10trans-

In the diabetic rat model, spironolactone treatment was associated with a reduction in urinary albumin excretion and amelioration of glomerulosclerosis despite no change in blood pressure. In various organs including the kidney, there is a local system for aldosterone generation. High glucose stimulates the expression of CYP 11B2 and mineralocorticoid receptor. Spironolactone in addition to blockade of the aldosterone receptor, was also able to reduce intrinsic renal ACE and also aldosterone synthase gene (CYP 11B2) expression in the streptozotocin-induced diabetic mice without affecting blood

Monocyte chemotactic protein (MCP-1) synthesis and nuclear factor-kB are markers of inflammation increased in renal tissue and in urine of diabetic rats and patients. In the cultured mesangial and proximal tubular cells there was inhibition of urinary excretion of MCP-1 (MCP-1) and its upstream transcription factor NF-kB suggesting that aldosterone

Transforming growth factor –B1 is a cytokine involved in ECM deposition, proliferation and fibrosis. Some of its tissue effects are mediated by connective tissue growth factor (CTGF). Aldosterone increases expression of TGF-1 and may directly induce CTGF. Spironolactone

mediated activation of proinflammatory cytokines was blocked (34).

In rats with 5/6th nephrectomy, adrenalectomy and protein restriction independently ameliorated the ablative nephropathy independent of the corticosterone maintenance level (16). In stroke-prone spontaneously hypertensive rats (SHRSP), renal vascular injury causing proteinuria and malignant nephrosclerotic lesions were markedly reduced by treatment with spironolactone (17). The effect of spironolactone alone was comparable to the effect of treatment with captopril. In another study the ameliorating effect of ACE-inhibition in the SHRSP rats could be fully reversed by infusion of aldosterone, suggesting a major additive role for aldosterone in the vascular injury in these rats(18). Importantly, the deleterious effects of aldosterone and the protective effects of spironolactone against renal damage in SHRSP rats appeared to be independent of the blood pressure.

Renal damage, as evidenced by albuminuria and glomerulosclerosis, in response to 5/6 nephrectomy was markedly less in mineralocorticoid resistant Wistar-Furth rats compared to Wistar rats. Treatment of hypertension in the nephrectomized Wistar rats did not protect them from renal injury(19), suggesting again that mineralocorticoid mediated deleterious effect was independent of the blood pressure.

Hyperaldosteronism has been noted as a component of clinical chronic renal insufficiency of various etiologies including diabetic nephropathy (20-21). In a cross sectional study of patients with mild to moderate renal insufficiency, Hene et al observed that the level of serum aldosterone increased several fold as creatinine clearance fell below 50% of normal (22). The significance of this hyperaldosteronism to the progression of the renal insufficiency has not been studied systematically, but in one longitudinal study Walker noted a significant correlation between aldosterone level and rate of progression of renal failure (23). In this longitudinal cohort study of 131 diabetics, Walker noted that hypertension, plasma angiotensin II and aldosterone were independent predictors of accelerated loss of renal function.

In vitro studies of cultured mesangial cells revealed increased production of type IV collagen after incubation with aldosterone (24-25). In addition to the classical genomic action through the type 1 mineralocorticoid receptor, aldosterone is now known to have significant non-genomic actions in many different tissues including kidney tubules, mesangial cells, podocytes and vascular smooth muscle cells. Aldosterone also up-regulates angiotensin II membrane receptors thereby multiplying the vascular effect of Ang II. This up-regulation is inhibited by treatment with spironolactone (26-30).

The renoprotective effects of MR blockers have been demonstrated in a variety of animal models. While the benefits were seen in most of these models , mechanism of the beneficial actions were deemed different in different models, depending on the primary focus of the investigators. One area of interest was ACE2 generation. Angiotensin II (which comes from angiotensinogen released by the liver which is converted to inactive Ang I by ACE and then to biologically active Ang II) acts mainly through the AT1 receptor to mediate vasoconstriction/proliferation and the AT2 receptor which mediates vasodilatation and antiproliferation. Ang(1-7) is generated from Ang II by ACE2 and counteracts some of the biologic effects of Ang II. In the Dahl-sensitive hypertensive rat fed a high salt diet, treatment with epleronone normalized blood pressure and decreased the levels of type IV collagen mRNA, angiotensinogen and ACE mRNA, but did not affect ACE2mRNA expression and is possibly protective by decreasing the formation of angiotensin II but not vasodilatory Ang (1-7). On the other hand, candesartan increased ACE 2 mRNA expression, suggesting that aldosterone blockade and angiotensin receptor blockade may be complimentary (31). Treatment with epleronone also reduced urinary protein excretion,

In rats with 5/6th nephrectomy, adrenalectomy and protein restriction independently ameliorated the ablative nephropathy independent of the corticosterone maintenance level (16). In stroke-prone spontaneously hypertensive rats (SHRSP), renal vascular injury causing proteinuria and malignant nephrosclerotic lesions were markedly reduced by treatment with spironolactone (17). The effect of spironolactone alone was comparable to the effect of treatment with captopril. In another study the ameliorating effect of ACE-inhibition in the SHRSP rats could be fully reversed by infusion of aldosterone, suggesting a major additive role for aldosterone in the vascular injury in these rats(18). Importantly, the deleterious effects of aldosterone and the protective effects of spironolactone against renal

Renal damage, as evidenced by albuminuria and glomerulosclerosis, in response to 5/6 nephrectomy was markedly less in mineralocorticoid resistant Wistar-Furth rats compared to Wistar rats. Treatment of hypertension in the nephrectomized Wistar rats did not protect them from renal injury(19), suggesting again that mineralocorticoid mediated deleterious

Hyperaldosteronism has been noted as a component of clinical chronic renal insufficiency of various etiologies including diabetic nephropathy (20-21). In a cross sectional study of patients with mild to moderate renal insufficiency, Hene et al observed that the level of serum aldosterone increased several fold as creatinine clearance fell below 50% of normal (22). The significance of this hyperaldosteronism to the progression of the renal insufficiency has not been studied systematically, but in one longitudinal study Walker noted a significant correlation between aldosterone level and rate of progression of renal failure (23). In this longitudinal cohort study of 131 diabetics, Walker noted that hypertension, plasma angiotensin

In vitro studies of cultured mesangial cells revealed increased production of type IV collagen after incubation with aldosterone (24-25). In addition to the classical genomic action through the type 1 mineralocorticoid receptor, aldosterone is now known to have significant non-genomic actions in many different tissues including kidney tubules, mesangial cells, podocytes and vascular smooth muscle cells. Aldosterone also up-regulates angiotensin II membrane receptors thereby multiplying the vascular effect of Ang II. This up-regulation is

The renoprotective effects of MR blockers have been demonstrated in a variety of animal models. While the benefits were seen in most of these models , mechanism of the beneficial actions were deemed different in different models, depending on the primary focus of the investigators. One area of interest was ACE2 generation. Angiotensin II (which comes from angiotensinogen released by the liver which is converted to inactive Ang I by ACE and then to biologically active Ang II) acts mainly through the AT1 receptor to mediate vasoconstriction/proliferation and the AT2 receptor which mediates vasodilatation and antiproliferation. Ang(1-7) is generated from Ang II by ACE2 and counteracts some of the biologic effects of Ang II. In the Dahl-sensitive hypertensive rat fed a high salt diet, treatment with epleronone normalized blood pressure and decreased the levels of type IV collagen mRNA, angiotensinogen and ACE mRNA, but did not affect ACE2mRNA expression and is possibly protective by decreasing the formation of angiotensin II but not vasodilatory Ang (1-7). On the other hand, candesartan increased ACE 2 mRNA expression, suggesting that aldosterone blockade and angiotensin receptor blockade may be complimentary (31). Treatment with epleronone also reduced urinary protein excretion,

II and aldosterone were independent predictors of accelerated loss of renal function.

damage in SHRSP rats appeared to be independent of the blood pressure.

effect was independent of the blood pressure.

inhibited by treatment with spironolactone (26-30).

renal injury scores and decreased (pro)renin receptor protein expression, angiotensinogen and AT1R mRNA levels and kidney Ang II content in the same rat model. (32)

Fig. 1. Angiotensin-Aldosterone Axis and the Physiologic Effects of Aldosterone *ROS* Reactive Oxygen Species, *AT1* Angiotensin I, *EKODE* epoxy-9keto-10transoctadecenoic acid, *SMC* smooth muscle cell

In the diabetic rat model, spironolactone treatment was associated with a reduction in urinary albumin excretion and amelioration of glomerulosclerosis despite no change in blood pressure. In various organs including the kidney, there is a local system for aldosterone generation. High glucose stimulates the expression of CYP 11B2 and mineralocorticoid receptor. Spironolactone in addition to blockade of the aldosterone receptor, was also able to reduce intrinsic renal ACE and also aldosterone synthase gene (CYP 11B2) expression in the streptozotocin-induced diabetic mice without affecting blood sugar or blood pressure (33).

Monocyte chemotactic protein (MCP-1) synthesis and nuclear factor-kB are markers of inflammation increased in renal tissue and in urine of diabetic rats and patients. In the cultured mesangial and proximal tubular cells there was inhibition of urinary excretion of MCP-1 (MCP-1) and its upstream transcription factor NF-kB suggesting that aldosterone mediated activation of proinflammatory cytokines was blocked (34).

Transforming growth factor –B1 is a cytokine involved in ECM deposition, proliferation and fibrosis. Some of its tissue effects are mediated by connective tissue growth factor (CTGF). Aldosterone increases expression of TGF-1 and may directly induce CTGF. Spironolactone

Diabetic Nephropathy: Role of Aldosterone and

Benefits of Therapy with Aldosterone Receptor Blocker 45

During the progression of renal damage, aldosterone might be involved in injury to the glomerular podocytes, mesangium, tubulointerstitium and tubules through locally expressed Mineralocorticoid receptor (MR).(46-48) However, the precise molecular mechanisms responsible for aldosterone and MR-induced cell injury are unclear. In the kidney, aldosterone activates multiple intracellular mechanisms including reactive oxygen species, mitogen-activated protein kinases (MAPKs) and Rho-kinase etc. by activating

The renoprotective effects of spironolactone or epleronone had been seen in many other animal models of renal injury not limited to diabetic nephropathy, as noted in a recent review by Nishiyama et al. (46) These models included streptozotocin-induced and other forms of diabetic rats and mice, obese SHR rats, murine lupus nephritis, unilateral ureteral obstruction, ischemia reperfusion injury, 5/6th nephrectomised rats and rats treated with AngII infusion, NO synthase inhibitor or cyclosporine( 53-66). In these animal models, treatment with aldosterone blockers had no effect on systemic blood pressure. Thus, these observations are consistent with the concept that aldosterone and MR-dependent renal

Metabolic syndrome with or without diabetes causes podocyte injury and progressive nephropathy. In type 2 diabetes, coexistent metabolic syndrome plays a synergistic role in progressive renal injury. Nagase et al investigated the role of aldosterone signaling in rats with metabolic syndrome(67). Proteinuria was prominent in SHR/NDmcr-cp compared with nonobese SHR, which was accompanied by podocyte injury as evidenced by foot process effacement, induction of desmin and attenuation of nephrin. Serum aldosterone level, renal and glomerular expression of aldosterone effector kinase Sgk1, and oxidative stress markers all were elevated in SHR/NDmcr-cp. Mineralocorticoid receptors were expressed in glomerular podocytes. Eplerenone treatment effectively reduced podocyte damage, proteinuria, Sgk1, and oxidant stress. Pretreatment with antioxidant tempol also

When these investigators looked for the source of the excess aldosterone , it was found that visceral adipocytes, isolated from SHR/NDmcr-cp, secreted substances that stimulated aldosterone production in adrenocortical cells. The aldosterone-releasing activity of adipocytes was not inhibited by candesartan. Adipocytes from nonobese SHR did not show such activity. That visceral adipocytes may be the source of factors causing excess aldosterone was , however, first noted by Ehrhart-Bornstein et al (68) and later the secreted factor was further characterized as EKODE (12,13-epoxy-9keto-10(trans)-octadecenoic acid) by Goodfriend et al. (69) These are mainly oxidized polyunsaturated fatty acids produced by adipocytes. One of the most potent one is an oxidized product of linoleic acid (EKODE). EKODE stimulated aldosteronogenesis at concentrations from 0.5 to 5 micromol/L but inhibited it at higher dose. In samples from 24 adults levels of EKODE correlated directly with aldosterone level and in a subsample of 12 blacks in the cohort it correlated with body mass index and systolic blood pressure. The resistant hypertension seen in patients with abdominal obesity is partly due to these autacoids secreted by visceral adipocytes, and BP in these patients respond very well to the use of spironolactone. This may explain the observation in the Framingham study that plasma aldosterone concentration was

MR(49-50). These molecular mechanisms have been reviewed recently(51-52).

injury is not dependent on blood pressure changes but on their local actions.

alleviated podocyte impairment and proteinuria, along with inhibition of Sgk1.

significantly correlated with the risk of onset of the metabolic syndrome.

reduced TGF-B1 expression and CTGF and renal collagen synthesis through a TGF-B1 independent pathway (not inhibited by prior TGF-B1 neutralization). (35)

Plasminogen Activator inhibitor (PAI-1) inhibits fibrinolysis and mediates ECM accumulation in mesangial and fibroblast cells and glomerulosclerosis. Its synthesis is induced by aldosterone and potentiated by the presence of TGF-B1. Spironolactone treatment reduced expression of PAI-1 and TGF-b in streptozotocin-induced diabetic rats and improves the antioxidant environment by reducing the fall in superoxide dismutase and glutathione peroxidase that accompanies diabetes induction resulting in reduced malondialdehyde levels (lipid oxidation byproduct) (36).

VEGF is a cytokine involved in the early development of diabetic nephropathy and its expression is increased by glucose, AGE, TGF-B1 and IGF-1. Aldosterone infusion increases renal VEGF synthesis. Spironolactone alone and in combination with losartan reduced VEGF, MCP-1 and malondialdehyde expression resulting in reduced mesangial expansion and sclerosis in an OLETF model. (37)

Aldosterone inhibition was also useful in reducing blood pressure and renal injury in diabetic mice which had impaired endothelial nitric oxide response induced by eNOS knockout. These mice did not have good response to ACE or ARB therapy. (38).

Recent studies have also investigated the effects of epleronone alone or in addition to ACE or ARB therapy in the diabetic rat. Mineralocorticoid receptor (MR) expression is increased in diabetic rats (OLETF) and epleronone reduced cortical levels of MR protein, MR RNA, TGF–b mRNA and osteopontin mRNA and improved various histological measures of renal injury along with albuminuria (39). The combination of epleronone and enalapril resulted in greatest decrease in TGF-b, Type IV collagen and TPA-1 expression both in the whole kidney and in cultured mesangial cells accompanied by an improvement in albuminuria, GFR and glomerulosclerosis compared to either agent alone. (40). In streptozotocin diabetic rats, the addition of epleronone with ramipril prevented glomerular hyperfiltration but did not have an additive effect on proteinuria or glomerular hypertrophy (41). Again in OLETF diabetic rats, epleronone added to telmisartan did not alter systolic blood pressure but resulted in greater reduction in proteinuria and podocyte injury and a greater increase in nephrin and podocin mRNA levels. Hydralazine decreased SBP but did not alter any of the renal parameters. (42)

Epleronone protected against podocyte damage in the hypertensive rat model as evidenced by reduced expression of podocyte injury markers desmin and B7-1. Mechanisms involved include inhibition of NADPH oxidase (p22phox and gp91phox), which is induced by aldosterone and generates reactive oxygen species , and reduced aldosterone effector kinase Sgk1, which is involved in diabetes stimulated matrix deposition. Unlike epleronone, hydralazine did not improve proteinuria or marker expression despite equivalent BP control. Local expression of apoptosis related molecules (caspase-3 and Bax) as well as reduction of BCl-2 (apoptosis regulatory protein) in podocytes of diabetic rats was prevented by treatment with spironolactone. Based on these studies, Shibata et al surmised that it is possible that Sgk1 plays a key role as the common effector molecule of the MR signaling in podocytes. (43-45)

reduced TGF-B1 expression and CTGF and renal collagen synthesis through a TGF-B1

Plasminogen Activator inhibitor (PAI-1) inhibits fibrinolysis and mediates ECM accumulation in mesangial and fibroblast cells and glomerulosclerosis. Its synthesis is induced by aldosterone and potentiated by the presence of TGF-B1. Spironolactone treatment reduced expression of PAI-1 and TGF-b in streptozotocin-induced diabetic rats and improves the antioxidant environment by reducing the fall in superoxide dismutase and glutathione peroxidase that accompanies diabetes induction resulting in reduced

VEGF is a cytokine involved in the early development of diabetic nephropathy and its expression is increased by glucose, AGE, TGF-B1 and IGF-1. Aldosterone infusion increases renal VEGF synthesis. Spironolactone alone and in combination with losartan reduced VEGF, MCP-1 and malondialdehyde expression resulting in reduced mesangial expansion

Aldosterone inhibition was also useful in reducing blood pressure and renal injury in diabetic mice which had impaired endothelial nitric oxide response induced by eNOS

Recent studies have also investigated the effects of epleronone alone or in addition to ACE or ARB therapy in the diabetic rat. Mineralocorticoid receptor (MR) expression is increased in diabetic rats (OLETF) and epleronone reduced cortical levels of MR protein, MR RNA, TGF–b mRNA and osteopontin mRNA and improved various histological measures of renal injury along with albuminuria (39). The combination of epleronone and enalapril resulted in greatest decrease in TGF-b, Type IV collagen and TPA-1 expression both in the whole kidney and in cultured mesangial cells accompanied by an improvement in albuminuria, GFR and glomerulosclerosis compared to either agent alone. (40). In streptozotocin diabetic rats, the addition of epleronone with ramipril prevented glomerular hyperfiltration but did not have an additive effect on proteinuria or glomerular hypertrophy (41). Again in OLETF diabetic rats, epleronone added to telmisartan did not alter systolic blood pressure but resulted in greater reduction in proteinuria and podocyte injury and a greater increase in nephrin and podocin mRNA levels. Hydralazine decreased SBP but did not alter any of the

Epleronone protected against podocyte damage in the hypertensive rat model as evidenced by reduced expression of podocyte injury markers desmin and B7-1. Mechanisms involved include inhibition of NADPH oxidase (p22phox and gp91phox), which is induced by aldosterone and generates reactive oxygen species , and reduced aldosterone effector kinase Sgk1, which is involved in diabetes stimulated matrix deposition. Unlike epleronone, hydralazine did not improve proteinuria or marker expression despite equivalent BP control. Local expression of apoptosis related molecules (caspase-3 and Bax) as well as reduction of BCl-2 (apoptosis regulatory protein) in podocytes of diabetic rats was prevented by treatment with spironolactone. Based on these studies, Shibata et al surmised that it is possible that Sgk1 plays a key role as the common effector molecule of the MR

knockout. These mice did not have good response to ACE or ARB therapy. (38).

independent pathway (not inhibited by prior TGF-B1 neutralization). (35)

malondialdehyde levels (lipid oxidation byproduct) (36).

and sclerosis in an OLETF model. (37)

renal parameters. (42)

signaling in podocytes. (43-45)

During the progression of renal damage, aldosterone might be involved in injury to the glomerular podocytes, mesangium, tubulointerstitium and tubules through locally expressed Mineralocorticoid receptor (MR).(46-48) However, the precise molecular mechanisms responsible for aldosterone and MR-induced cell injury are unclear. In the kidney, aldosterone activates multiple intracellular mechanisms including reactive oxygen species, mitogen-activated protein kinases (MAPKs) and Rho-kinase etc. by activating MR(49-50). These molecular mechanisms have been reviewed recently(51-52).

The renoprotective effects of spironolactone or epleronone had been seen in many other animal models of renal injury not limited to diabetic nephropathy, as noted in a recent review by Nishiyama et al. (46) These models included streptozotocin-induced and other forms of diabetic rats and mice, obese SHR rats, murine lupus nephritis, unilateral ureteral obstruction, ischemia reperfusion injury, 5/6th nephrectomised rats and rats treated with AngII infusion, NO synthase inhibitor or cyclosporine( 53-66). In these animal models, treatment with aldosterone blockers had no effect on systemic blood pressure. Thus, these observations are consistent with the concept that aldosterone and MR-dependent renal injury is not dependent on blood pressure changes but on their local actions.

Metabolic syndrome with or without diabetes causes podocyte injury and progressive nephropathy. In type 2 diabetes, coexistent metabolic syndrome plays a synergistic role in progressive renal injury. Nagase et al investigated the role of aldosterone signaling in rats with metabolic syndrome(67). Proteinuria was prominent in SHR/NDmcr-cp compared with nonobese SHR, which was accompanied by podocyte injury as evidenced by foot process effacement, induction of desmin and attenuation of nephrin. Serum aldosterone level, renal and glomerular expression of aldosterone effector kinase Sgk1, and oxidative stress markers all were elevated in SHR/NDmcr-cp. Mineralocorticoid receptors were expressed in glomerular podocytes. Eplerenone treatment effectively reduced podocyte damage, proteinuria, Sgk1, and oxidant stress. Pretreatment with antioxidant tempol also alleviated podocyte impairment and proteinuria, along with inhibition of Sgk1.

When these investigators looked for the source of the excess aldosterone , it was found that visceral adipocytes, isolated from SHR/NDmcr-cp, secreted substances that stimulated aldosterone production in adrenocortical cells. The aldosterone-releasing activity of adipocytes was not inhibited by candesartan. Adipocytes from nonobese SHR did not show such activity. That visceral adipocytes may be the source of factors causing excess aldosterone was , however, first noted by Ehrhart-Bornstein et al (68) and later the secreted factor was further characterized as EKODE (12,13-epoxy-9keto-10(trans)-octadecenoic acid) by Goodfriend et al. (69) These are mainly oxidized polyunsaturated fatty acids produced by adipocytes. One of the most potent one is an oxidized product of linoleic acid (EKODE). EKODE stimulated aldosteronogenesis at concentrations from 0.5 to 5 micromol/L but inhibited it at higher dose. In samples from 24 adults levels of EKODE correlated directly with aldosterone level and in a subsample of 12 blacks in the cohort it correlated with body mass index and systolic blood pressure. The resistant hypertension seen in patients with abdominal obesity is partly due to these autacoids secreted by visceral adipocytes, and BP in these patients respond very well to the use of spironolactone. This may explain the observation in the Framingham study that plasma aldosterone concentration was significantly correlated with the risk of onset of the metabolic syndrome.

Diabetic Nephropathy: Role of Aldosterone and

among the three groups.

Benefits of Therapy with Aldosterone Receptor Blocker 47

combination resulted in a further reduction. The blood pressure reduction was the same

A review of the studies where spironolactone was used as single-drug or dual-drug add-on, the degree of albuminuria or proteinuria reduction was about 30-35% with a trend towards a further reduction in studies that had an extended period of observation of up to a year (76). The reduction in albuminuria was greater when spironolactone was used as singledrug add on compared to dual-drug add on (although one study (80) reported an impressive 58% reduction). The addition of spironolactone to baseline ACE-I (lisinopril) therapy resulted in greater reduction in albuminuria compared to the addition of an ARB agent (losartan) to baseline ACE-I (74). This was confirmed in another study that demonstrated that the addition of spironolactone to either single-drug (ramipril) or dualdrug (ramipril + irbesartan) baseline therapy resulted in further reduction in albuminuria but the addition of ARB alone to the ACE-I did not further reduce albuminuria. (75). Several studies correlated the degree of proteinuria reduction to a drop in GFR and to the preexisting serum aldosterone level. Urinary type IV collagen, which is stimulated by

The efficacy of spironolactone as add-on agent in patients with uncontrolled hypertension specifically those with features of aldosterone excess, such as obesity and low serum potassium levels, has been demonstrated in several studies . The reduction of systolic BP in these studies exceeds 20 mmHg. In the studies we are reviewing on diabetic nephropathy, most of whom again, were already on preexisting ACE-I and ARB therapy, the focus of the aldosterone antagonist add-on was on proteinuria and renal function. The reduction in BP was more modest. When used as single-agent add-on, several studies show a drop of 6-8 mmHg in systolic BP or ABPM with an additional smaller reduction with longer followup. One study showed no further drop in blood pressure, but this group of patients had overall a very high GFR (73). Addition of epleronone to enalapril produced only a non-significant change in BP (22). Spironolactone used as dual-drug add-on generally did not further reduce BP (75). There has been controversy among researchers in the field as to whether the reduction in proteinuria with aldosterone antagonists is a result purely of further BP lowering, but these studies demonstrate that it is much easier to show a reduction of

proteinuria that is statistically significant compared to a reduction in blood pressure.

The study results regarding the effects of aldosterone antagonists on renal function must be interpreted with caution. First of all, most of the studies followed renal function through measurement of serum creatinine or an estimation of GFR mathematically derived from creatinine levels, and it is well recognized that this is an insensitive marker to small changes in renal function. One exception are the studies from Denmark (26) which actually measured GFR directly. Secondly, the studies all excluded patients with Stage 4 and 5 CKD., and in fact the mean baseline GFR in most studies exceeded 60 ml/minute, and there are not enough patients in Stage 3 CKD to really draw any meaningful conclusions as to the effects of aldosterone antagonists on patients with more advanced CKD. With these caveats, the published studies indicate that the effect of spironolactone or epleronone on GFR is comparable to the effect of initiation of ACE-I or ARB agents . Single-drug add-on in most studies resulted in a 3-5 ml/min drop in GFR, while dual-agent add-on caused no further drop in GFR. The effects are most prominent in the first month or two after initiation, and drop in GFR is greater in those with baseline impaired function. One study in particular showed a sharp 13 ml/min decrease in GFR with spironolactone compared to baseline ACE-I or ARB therapy, but this decrease occurred early and eventually leveled off. Associated

aldosterone and is a reflection of renal fibrosis, was also decreased. (73,80)

Fig. 2. Mechanisms of genomic (long term) and nongenomic (rapid) effects of aldosterone. Aldosterone activates the tyrosine kinase c-Src through the production of ROS, leading to the activation of p38MAPK and also various signalling molecules like PKC, Akt, ERK ½, ERK5, Mapk7, and JNK. Aldosterone also mediates the activation of EGFR. Genomic and rapid effects of aldosterone lead to vascularremodeling, hypertrophy, inflammation, cell growth, apoptosis, adhesion, and migration. *Aldo* aldosterone, *EGFR* epidermal growth factor, *MR* mineralocorticoid receptor, *ROS* reactive oxygen species. Other abbreviations as in Fig. 1. (Ref. 93)

#### **2.1 Human studies using aldosterone receptor blockers**

Within the past decade, several human studies have been conducted exploring the effects of spironolactone and epleronone on patients with chronic kidney disease with or without diabetes between which we shall be concentrating on the latter.

Since ACE-I/ARB therapy had been generally accepted as standard therapy for patients with diabetic nephropathy, most studies conducted with aldosterone receptor blocker drug like spironolactone involved the addition of this agent to either single agent ACE-I or ARB (referred hence to as single- drug add-on) (70-74) or to combined ACE-I/ARB therapy (dual-drug addon) (75-76). Epleronone likewise has been tested as add-on therapy to enalapril (77-78).

In one study (79), albeit in non-diabetic patients, where spironolactone was compared headto-head to the ACE-I drug cilazapril along with the combination, it was found that spironolactone was slightly better at reducing albuminuria than cilazapril, but the

Fig. 2. Mechanisms of genomic (long term) and nongenomic (rapid) effects of aldosterone. Aldosterone activates the tyrosine kinase c-Src through the production of ROS, leading to the activation of p38MAPK and also various signalling molecules like PKC, Akt, ERK ½, ERK5, Mapk7, and JNK. Aldosterone also mediates the activation of EGFR. Genomic and rapid effects of aldosterone lead to vascularremodeling, hypertrophy, inflammation, cell growth, apoptosis, adhesion, and migration. *Aldo* aldosterone, *EGFR* epidermal growth factor, *MR* mineralocorticoid receptor, *ROS* reactive oxygen species. Other abbreviations as in Fig. 1.

Within the past decade, several human studies have been conducted exploring the effects of spironolactone and epleronone on patients with chronic kidney disease with or without

Since ACE-I/ARB therapy had been generally accepted as standard therapy for patients with diabetic nephropathy, most studies conducted with aldosterone receptor blocker drug like spironolactone involved the addition of this agent to either single agent ACE-I or ARB (referred hence to as single- drug add-on) (70-74) or to combined ACE-I/ARB therapy (dual-drug add-

In one study (79), albeit in non-diabetic patients, where spironolactone was compared headto-head to the ACE-I drug cilazapril along with the combination, it was found that spironolactone was slightly better at reducing albuminuria than cilazapril, but the

on) (75-76). Epleronone likewise has been tested as add-on therapy to enalapril (77-78).

**2.1 Human studies using aldosterone receptor blockers** 

diabetes between which we shall be concentrating on the latter.

(Ref. 93)

combination resulted in a further reduction. The blood pressure reduction was the same among the three groups.

A review of the studies where spironolactone was used as single-drug or dual-drug add-on, the degree of albuminuria or proteinuria reduction was about 30-35% with a trend towards a further reduction in studies that had an extended period of observation of up to a year (76). The reduction in albuminuria was greater when spironolactone was used as singledrug add on compared to dual-drug add on (although one study (80) reported an impressive 58% reduction). The addition of spironolactone to baseline ACE-I (lisinopril) therapy resulted in greater reduction in albuminuria compared to the addition of an ARB agent (losartan) to baseline ACE-I (74). This was confirmed in another study that demonstrated that the addition of spironolactone to either single-drug (ramipril) or dualdrug (ramipril + irbesartan) baseline therapy resulted in further reduction in albuminuria but the addition of ARB alone to the ACE-I did not further reduce albuminuria. (75). Several studies correlated the degree of proteinuria reduction to a drop in GFR and to the preexisting serum aldosterone level. Urinary type IV collagen, which is stimulated by aldosterone and is a reflection of renal fibrosis, was also decreased. (73,80)

The efficacy of spironolactone as add-on agent in patients with uncontrolled hypertension specifically those with features of aldosterone excess, such as obesity and low serum potassium levels, has been demonstrated in several studies . The reduction of systolic BP in these studies exceeds 20 mmHg. In the studies we are reviewing on diabetic nephropathy, most of whom again, were already on preexisting ACE-I and ARB therapy, the focus of the aldosterone antagonist add-on was on proteinuria and renal function. The reduction in BP was more modest. When used as single-agent add-on, several studies show a drop of 6-8 mmHg in systolic BP or ABPM with an additional smaller reduction with longer followup. One study showed no further drop in blood pressure, but this group of patients had overall a very high GFR (73). Addition of epleronone to enalapril produced only a non-significant change in BP (22). Spironolactone used as dual-drug add-on generally did not further reduce BP (75). There has been controversy among researchers in the field as to whether the reduction in proteinuria with aldosterone antagonists is a result purely of further BP lowering, but these studies demonstrate that it is much easier to show a reduction of proteinuria that is statistically significant compared to a reduction in blood pressure.

The study results regarding the effects of aldosterone antagonists on renal function must be interpreted with caution. First of all, most of the studies followed renal function through measurement of serum creatinine or an estimation of GFR mathematically derived from creatinine levels, and it is well recognized that this is an insensitive marker to small changes in renal function. One exception are the studies from Denmark (26) which actually measured GFR directly. Secondly, the studies all excluded patients with Stage 4 and 5 CKD., and in fact the mean baseline GFR in most studies exceeded 60 ml/minute, and there are not enough patients in Stage 3 CKD to really draw any meaningful conclusions as to the effects of aldosterone antagonists on patients with more advanced CKD. With these caveats, the published studies indicate that the effect of spironolactone or epleronone on GFR is comparable to the effect of initiation of ACE-I or ARB agents . Single-drug add-on in most studies resulted in a 3-5 ml/min drop in GFR, while dual-agent add-on caused no further drop in GFR. The effects are most prominent in the first month or two after initiation, and drop in GFR is greater in those with baseline impaired function. One study in particular showed a sharp 13 ml/min decrease in GFR with spironolactone compared to baseline ACE-I or ARB therapy, but this decrease occurred early and eventually leveled off. Associated

Diabetic Nephropathy: Role of Aldosterone and

Design of Study

59 (29 + 30)

41 / RCT-Parallel

addition to ACE inhibitor or ARB use in proteinuric patients.

Author/Year No. of Patients/

Epstein / 2002 141/(74 + 67)

Rachmani /2004 60/RCT-

Sato / 2005 32 /

Bianchi / 2005 42 /

Schjoedt / 2005 20 / RCT-

Rossing / 2005 21 / RCT-

Schjoedt / 2006 20 / RCT-

Bianchi / 2006 165 (82 + 83)

Epstein/2006 268/RCT-

Saklayen 2008 24/RCT-

Van den Meiracker / 2006

Chrysostomou /2006

Table 1.

Chrysostomou /

Benefits of Therapy with Aldosterone Receptor Blocker 49

Drugs/Dose/ Duration (Weeks)

RCT–Parallel EP / 200 / 12 19% 3/ - / -

Parallel SP / 100 / 24 19% --

Uncontrolled SP / 25 / 12 38% - / - / **↑**0.

Uncontrolled SP / 25 / 8 37% - / - / **↑**0.

Crossover SP / 25 / 8 30% **↓**8 / - / -

Crossover SP / 25 / 8 33% **↓**6 / **↓** 3 / -

RCT-Parallel SP / 25-50 / 8 41% **↓**7 / **↓** 8 / -

Crossover SP / 25 / 8 32% **↓**6 / **↓** 3 /**↑**0.

RCT–Parallel SP / 25 / 52 58% - / **<sup>↑</sup> <sup>↓</sup> /<sup>↑</sup>** 0.

Crossover SP / 25 / 12 57% ↓12 / ↓8 / ↑0.3

(4 group) 14% **↓**9/ **-** /**↑**0.

34%(low dose) **↓**4 / **<sup>↓</sup>** 6 / -

SP / 25 / 12

Parallel Ep/50-100/12 41%(high dose)

Ogawa 2006 30/RCT SP / 25 / 52 47% ↓11/ - / - Furumatsu 2008 25/RCT SP / 25 / 52 58% / - / -

Davidson 2008 24/Uncontrol SP / 25 / 4 26% ↓9 / - / - Mehdi 2009 81/ RCT SP/ 25 / 52 52% / - / ↑ Legend: Table showing summaries of the clinical studies done with aldosterone receptor blocker in

follow up was 1 year. And none of these studies examined the long term renal outcomes, especially progression to ESRD, need for dialysis or overall mortality. This paucity of clinical outcome studies is of major concern. Of note, when clinical studies of short duration showed additional lowering of microalbuminuria/proteinuria in diabetic nephropathy as well as in other proteinuric renal diseases, nephrologists became enthusiastic about dual use of ACEI and ARB in patients with diabetic nephropathy. When the large international

<sup>2001</sup>8 / Uncontrolled SP / 25 / 4 54%

Reduction in Proteinuria (%)

In Sys.BPmmHg/ GFRml/min/ Kmeq/L

1

4

2

2

8

with this was a sharp drop in albuminuria of 40%. Many studies confirm that the reduction in proteinuria correlates well with the degree in reduction of GFR.

Most of the adverse effects noted includes the known incidence of anti-androgenic effects of spironolactone and hyperkalemia which correlates with the dosage used. Epleronone is of course, free of the first set of side effects and generally results in less hyperkalemia, but this may be a function of the dosages currently being studied . Most studies excluded patients with baseline potassium exceeding 4.5 or 5.0 mmol/L. The trend of the results show that while dual-agent therapy had a greater tendency towards hyperkalemia when compared to single agent therapy, the addition of spironolactone to either ACE-I or ARB resulted in the highest risk of hyperkalemia. This complication may be more frequent among diabetics who tend to have hyporeninemic hypoaldosteronism and is definitely more prevalent in patients with lower baseline GFR, higher baseline potassium, and preexisting metabolic acidosis. With the background of the experience after publication of the RALES study, when practitioners promoted the use of spironolactone for heart failure in patients outside the inclusion criteria of the study, resulting in the appearance of several near fatal hyperkalemic episodes, it behooves us to follow the patients with more advanced CKD more closely and to check serum potassium agents earlier if we choose to use these agents for diabetic nephropathy. There was a suggestion that glucose tolerance worsened after spironolactone with a rise in Hba1c (70,81)), but this was not seen in other studies (78). Spironolactone may also decrease BNP over that achieved by ACE-I (84).

A small study conducted by these authors(82) using a randomized double-blind crossover design to study the effects of spironolactone when added to ACE-I or ARB shows similar results to the studies quoted above, in that spironolactone produced a 57% reduction in proteinuria along with a 7mmHg drop in systolic BP. This was accompanied by a rise in creatinine of about 0.2 mg/dl and serum potassium of 0.3 mEq/L.

The role of aldosterone antagonists in the treatment of diabetic nephropathy may lie in the group of patients whose blood pressure or proteinuria are uncontrolled despite ACE-I or ARB therapy, or who manifest so-called 'aldosterone escape" when aldosterone levels increase after long-term RAAS blockade. (83-84)). Table 1 lists all the clinical trials using Aldosterone receptor blockers in proteinuric patients. As shown in the table the range of proteinuria reduction with additional use of aldosterone receptor blocker was 19% to 58%.(70-87) Aldosterone antagonists seem to be more effective and more economical when added to ACE-I compared to ARBs at this time, albeit at the price of greater risk for acute GFR drop and hyperkalemia. Unfortunately, no long term studies are available at this time to demonstrate that renal function decline is slowed by this approach, and proteinuria is taken as a marker of disease progression, as was with ACE-I/ARB therapy at an earlier time point.

#### **3. Future direction**

The beneficial effects of mineralocorticoid/aldosterone receptor blockers in ameliorating or stopping the progression of diabetic nephropathy is impressive in in-vitro studies using mesangial, podocytes or endothelial cell culture system. These studies also help us understand the molecular mechanism by which these agents ameliorate the pathologic process. In-vivo animal model studies also showed encouraging results as elaborated in preceding pages. Similar benefits have been seen in human studies as summarized in the table 1. However most of the human studies were of relative short duration. Longest study

with this was a sharp drop in albuminuria of 40%. Many studies confirm that the reduction

Most of the adverse effects noted includes the known incidence of anti-androgenic effects of spironolactone and hyperkalemia which correlates with the dosage used. Epleronone is of course, free of the first set of side effects and generally results in less hyperkalemia, but this may be a function of the dosages currently being studied . Most studies excluded patients with baseline potassium exceeding 4.5 or 5.0 mmol/L. The trend of the results show that while dual-agent therapy had a greater tendency towards hyperkalemia when compared to single agent therapy, the addition of spironolactone to either ACE-I or ARB resulted in the highest risk of hyperkalemia. This complication may be more frequent among diabetics who tend to have hyporeninemic hypoaldosteronism and is definitely more prevalent in patients with lower baseline GFR, higher baseline potassium, and preexisting metabolic acidosis. With the background of the experience after publication of the RALES study, when practitioners promoted the use of spironolactone for heart failure in patients outside the inclusion criteria of the study, resulting in the appearance of several near fatal hyperkalemic episodes, it behooves us to follow the patients with more advanced CKD more closely and to check serum potassium agents earlier if we choose to use these agents for diabetic nephropathy. There was a suggestion that glucose tolerance worsened after spironolactone with a rise in Hba1c (70,81)), but this was not seen in other studies (78). Spironolactone may

A small study conducted by these authors(82) using a randomized double-blind crossover design to study the effects of spironolactone when added to ACE-I or ARB shows similar results to the studies quoted above, in that spironolactone produced a 57% reduction in proteinuria along with a 7mmHg drop in systolic BP. This was accompanied by a rise in

The role of aldosterone antagonists in the treatment of diabetic nephropathy may lie in the group of patients whose blood pressure or proteinuria are uncontrolled despite ACE-I or ARB therapy, or who manifest so-called 'aldosterone escape" when aldosterone levels increase after long-term RAAS blockade. (83-84)). Table 1 lists all the clinical trials using Aldosterone receptor blockers in proteinuric patients. As shown in the table the range of proteinuria reduction with additional use of aldosterone receptor blocker was 19% to 58%.(70-87) Aldosterone antagonists seem to be more effective and more economical when added to ACE-I compared to ARBs at this time, albeit at the price of greater risk for acute GFR drop and hyperkalemia. Unfortunately, no long term studies are available at this time to demonstrate that renal function decline is slowed by this approach, and proteinuria is taken as a marker of

The beneficial effects of mineralocorticoid/aldosterone receptor blockers in ameliorating or stopping the progression of diabetic nephropathy is impressive in in-vitro studies using mesangial, podocytes or endothelial cell culture system. These studies also help us understand the molecular mechanism by which these agents ameliorate the pathologic process. In-vivo animal model studies also showed encouraging results as elaborated in preceding pages. Similar benefits have been seen in human studies as summarized in the table 1. However most of the human studies were of relative short duration. Longest study

in proteinuria correlates well with the degree in reduction of GFR.

also decrease BNP over that achieved by ACE-I (84).

**3. Future direction** 

creatinine of about 0.2 mg/dl and serum potassium of 0.3 mEq/L.

disease progression, as was with ACE-I/ARB therapy at an earlier time point.


Legend: Table showing summaries of the clinical studies done with aldosterone receptor blocker in addition to ACE inhibitor or ARB use in proteinuric patients.

Table 1.

follow up was 1 year. And none of these studies examined the long term renal outcomes, especially progression to ESRD, need for dialysis or overall mortality. This paucity of clinical outcome studies is of major concern. Of note, when clinical studies of short duration showed additional lowering of microalbuminuria/proteinuria in diabetic nephropathy as well as in other proteinuric renal diseases, nephrologists became enthusiastic about dual use of ACEI and ARB in patients with diabetic nephropathy. When the large international

Diabetic Nephropathy: Role of Aldosterone and

1996;39(5):587-593.

JMed. 2001;345:870-878.

J Med.2001;345:861-869.

2003;26:2268-2274.

2000;57:601-606.

Apr;10(4):814-21

Sep;17(3):261-9

Kidney Int. 2003;63:1874-1880.

met-analysis. Lancet 2005; 10:366:2026-33.

the rat. J Clin Invest. 1996;98(4):1063-1068.

Benefits of Therapy with Aldosterone Receptor Blocker 51

[3] Ravid M, Savin H, Jutrin I, et al. Long-term stabilizing effect of angiotensin-converting

[4] The Microalbuminuria Captopril Study Group. Captopril reduces the risk of

[5] Parving H-H, Lehnert H, Bro¨chner-Mortensen J, et al. The effects of Irbesartan on the

[6] Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and

[7] Rossing K, Jacobsen P, Pietraszek L, et al. Reno protective effects of adding angiotensin II

[8] Andersen S, Tarnow L, Rossing P, et al. Reno protective effects of angiotensin II receptor

[9] Jacobsen P, Andersen S, Rossing K, et al. Dual blockade of the rennin-angiotensin system

[10] Sarafidis PA, Stafylas PC, Kanaki AI et al. Effects of renin-angiotensin system blockers

[11] Casas JP, Chua W, Loukogeorgakis S et al. Effects of inhibitors of the renin-angiotensin

[12] De Boer IH, Rue TC , Hall YN et al. Temporal trends in the prevalence of Diabetic

[13] Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med. 1999;341:709-717. [14] Ritz E and Tomaschitz A. Aldosterone, a vasculotoxic agent0 novel functions for an old

[15] Greene EL, Kren S, Hostetter TH. Role of aldosterone in the remnant kidney model in

[16] Quan ZY, Walser M, Hill GS. Adrenalectomy ameliorates ablative nephropathy in the rat independently of corticosterone maintenance level. Kidney Int. 1992;41:326-33. [17] Rocha R, Chander PN, Khanna K, et al. Mineralocorticoid blockade reduces vascular injury in stroke-prone hypertensive rats. Hypertension. 1998; 31:451-58. [18] Rocha R, Chander PN, Zuckerman A, et al. Role of aldosterone in renal vascular injury

[19] Fitzgibbon WR, Greene EL, Grewal JS, Hutchison FN, Self SE, Latten SY, Ulian ME:

[20] Ferriss JB, Sullivan PA, Gonggrijp H, Cole M, O'Sullivan DJ: Plasma angiotensin II and

Resistance to remnant nephropathy in the Wistar-Furth rat. J Am Soc Nephrol 1999

aldosterone in unselected diabetic patients. Clin Endocrinol (Oxf) 1982

Kidney diseases in the United States. JAMA 2011; 305:2532-2539.

in stroke-prone hypertensive rats. Hypertension. 1999; 33:232-37.

an updated meta-analysis. Am J. Hypertens 2008; 21;922-9.

hormone. Nephrol Dial Transplant 2009; 24:2302-2305.

diabetic patients. Ann Intern Med. 1993;118(8):577-581.

enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II

nephropathy in IDDM patients with microalbuminuria. Diabetologia.

development of diabetic nephropathy in patients with type 2 diabetes. N Engl

cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl

receptor blocker to maximal recommended doses of ACE inhibitor in diabetic nephropathy: a randomized double-blind crossover trial. Diabetes Care.

blockade in type 1 diabetic patients with diabetic nephropathy. Kidney Int.

versus maximal recommended dose of ACE inhibition in diabetic nephropathy.

on renal outcomes and all cause mortality in patients with diabetic nephropathy:

system and other antihypertensive drugs on renal outcomes: systemic review and

ONTARGET study showed that renal outcomes (GFR deterioration, incidence of ESRD, need for dialysis and incidence of hyperkalemia) in diabetic nephropathy of patients on dual therapy was worse than on single agent therapy ( ACEI or ARB alone), that initial enthusiasm was checked. (88) Dual ACEI and ARB use is no longer recommended in patients with diabetic nephropathy except in extraordinary situations.

However, the long term outcomes of MR/aldo blocker therapy with ACEI or ARB in diabetic nephropathy need not be similarly detrimental or non-beneficial. Of note while ONTARGET failed to show cardiovascular benefits with dual ACEI and ARB use and other studies showed lack of mortality benefits in dual use of ACEI and ARB in systolic heart failure(89), RALES and other studies (90) showed significant mortality benefit of adding spironolactone or epleronone to ACE or ARB in systolic heart failure patients. However, unless large clinical outcome studies confirm that adding aldosterone blockade to ACEI or ARB actually results in reduction of ESRD incidence, such therapy cannot be recommended without some caution.

When we did our small cross over study in a single institute, we selected patients carefully. Those patients who had hyperkalemia , even remotely, were excluded from participation. Most of our patients also were using high dose thiazide or loop diuretics. Our study, like many other similar studies, were of few weeks duration. As shown in POST RALES study, the incidence of hyperkalemia in Ontario was much higher than seen in the RALES study itself , when spironolactone use became widespread for systolic heart failure. (91)

Questions often arise if one were to use an aldosterone receptor blocker, which one to choose. Spironolactone is the first mineralocorticoid receptor antagonist (MRA) which has been in clinical use for over half a century. Epleronone is a relatively new mineralocorticoid receptor blocker and is still under patent protection. Compared to the latter, spironolactone blocks the androgen and progesterone receptors in addition to its primary blocking effects on mineralocorticoid receptors. This leads to some unpleasant problem of gynecomastia in male patients, the incidence of which is about 10%. Epleronone is much less likely to cause gynecomastia. But binding affinity of epleronone for MR is much lower than that of spironolactone. Spironolactone also has 3 active metabolites all of which have prolonged half life. Epleronone has half life of4-6 hours and its metabolites are not active. Because of these pharmacological and pharmacodynamic differences, spironolactone seems to be a clinically more effective MR blocking agent than epleronone. One recent comparison of treatment with spironolactone (75 to 225 mg daily ) vs epleronone (100 to 300 mg daily) in patients with primary hyperaldosteronism showed better blood pressure lowering by spironolactone (diastolic BP reduction 12.5 mmHg in former vs 5.6 mmHg in later group). There has not been a head to head comparison of the two MR blockers in trials looking for a reduction of proteinuria or improvement in survival in patients with systolic dysfunction. (92)

#### **4. References**


ONTARGET study showed that renal outcomes (GFR deterioration, incidence of ESRD, need for dialysis and incidence of hyperkalemia) in diabetic nephropathy of patients on dual therapy was worse than on single agent therapy ( ACEI or ARB alone), that initial enthusiasm was checked. (88) Dual ACEI and ARB use is no longer recommended in

However, the long term outcomes of MR/aldo blocker therapy with ACEI or ARB in diabetic nephropathy need not be similarly detrimental or non-beneficial. Of note while ONTARGET failed to show cardiovascular benefits with dual ACEI and ARB use and other studies showed lack of mortality benefits in dual use of ACEI and ARB in systolic heart failure(89), RALES and other studies (90) showed significant mortality benefit of adding spironolactone or epleronone to ACE or ARB in systolic heart failure patients. However, unless large clinical outcome studies confirm that adding aldosterone blockade to ACEI or ARB actually results in reduction of ESRD incidence, such therapy cannot be recommended

When we did our small cross over study in a single institute, we selected patients carefully. Those patients who had hyperkalemia , even remotely, were excluded from participation. Most of our patients also were using high dose thiazide or loop diuretics. Our study, like many other similar studies, were of few weeks duration. As shown in POST RALES study, the incidence of hyperkalemia in Ontario was much higher than seen in the RALES study

Questions often arise if one were to use an aldosterone receptor blocker, which one to choose. Spironolactone is the first mineralocorticoid receptor antagonist (MRA) which has been in clinical use for over half a century. Epleronone is a relatively new mineralocorticoid receptor blocker and is still under patent protection. Compared to the latter, spironolactone blocks the androgen and progesterone receptors in addition to its primary blocking effects on mineralocorticoid receptors. This leads to some unpleasant problem of gynecomastia in male patients, the incidence of which is about 10%. Epleronone is much less likely to cause gynecomastia. But binding affinity of epleronone for MR is much lower than that of spironolactone. Spironolactone also has 3 active metabolites all of which have prolonged half life. Epleronone has half life of4-6 hours and its metabolites are not active. Because of these pharmacological and pharmacodynamic differences, spironolactone seems to be a clinically more effective MR blocking agent than epleronone. One recent comparison of treatment with spironolactone (75 to 225 mg daily ) vs epleronone (100 to 300 mg daily) in patients with primary hyperaldosteronism showed better blood pressure lowering by spironolactone (diastolic BP reduction 12.5 mmHg in former vs 5.6 mmHg in later group). There has not been a head to head comparison of the two MR blockers in trials looking for a reduction of

itself , when spironolactone use became widespread for systolic heart failure. (91)

proteinuria or improvement in survival in patients with systolic dysfunction. (92)

[1] Lewis EJ, Hunsicker LG, Bain RP, et al. The effect of angiotensin-converting-enzyme

[2] Viberti G, Mogensen CE, Groop LC, et al. Effect ofcaptopril on progression to clinical

inhibition on diabetic nephropathy.The Collaborative Study Group. N Engl J

proteinuria in patientswith insulin-dependent diabetes mellitus and microalbuminuria. European Microalbuminuria Captopril Study Group. JAMA. 1994;271(4):275-279.

patients with diabetic nephropathy except in extraordinary situations.

without some caution.

**4. References** 

Med.1993;329(20):1456-1462.


Diabetic Nephropathy: Role of Aldosterone and

2, February 2010

Benefits of Therapy with Aldosterone Receptor Blocker 53

[37] Lee MY, Shim MS, Kim BH, Hong SW, Choi R, Lee EY, Nam SM, Kim GW, Shin JY,

[39] Christine Guo, Diego Martinez-Vasquez, Gonzalo P. Mendez, Maria F. Toniolo, Tham

[40] Kang, Young Sun1; Ko, Gang Jee2; Lee, Mi Hwa3; Song, Hye Kyoung1; Han, Sang

Types 1 and 2 Diabetes Mellitus. *Endocrinology* 2006 147: 5363-5373;

Diabetic Rats. *Pharmacology* 2010;86:85-91 (DOI: 10.1159/000316113) [42] Akira Nishiyama, Hiroyuki Kobori, Yoshio Konishi, Takashi Morikawa, Isseki Maeda,

aldosterone blocker. *Hypertension* 2006 June;47(6):1084-93.

receptor blockers.J Pharmacol Sci. 2009 Jan;109(1):1-6

renal fibroblasts. Hypertension. 2005;46:1039–1045

Shin YG, Chung CH. Effects of Spironolactone and losartan on diabetic nephropathy in type 2 diabetic rat model. *Diabetes Metab J*. 2011 Apr;35(2):130-7. [38] Kosugi, Tomoki1,2; Heinig, Marcelo1; Nakayama, Takahiro1; Matsuo, Seiichi3;

Nakagawa, Takahiko1,2 . eNOS Knockout Mice with Advanced Diabetic Nephropathy Have Less Benefit from Renin-Angiotensin Blockade than from Aldosterone Receptor Antagonists. *The American Journal of Pathology*, Vol. 176, No.

M. Yao, Eveline M. Oestreicher, Taisuke Kikuchi, Nathalie Lapointe, Luminita Pojoga, Gordon H. Williams, Vincent Ricchiuti, and Gail K. Adler. Mineralocorticoid Receptor Antagonist Reduces Renal Injury in Rodent Models of

Youb1; Han, Kum Hyun1; Kim, Hyoung Kyu1; Han, Jee Young1; Cha, Dae Ryong1. Effect of eplerenone, enalapril and their combination treatment on diabetic nephropathy in type II diabetic rats. *Nephrol Dial Transplant* (2009) 24: 73–84. [41] Thomas A. Mavrakanasa, Angeliki Chevab, Konstantinos Kallarasc, Georgios

Karkavelasb, Maria Mironidou-Tzouvelekia. Effect of Ramipril Alone Compared to Ramipril with Eplerenone on Diabetic Nephropathy in Streptozocin-Induced

Michiaki Okumura, Masatsugu Kishida, Masahiro Hamada, Yukiko Nagai, Toshitaka Nakagawa, Naro Ohashi, Daisuke Nakano, Hirofumi Hitomi, and Masahito Imanishi. Mineralocorticoid Receptor Blockade Enhances the Antiproteinuric Effect of an Angiotensin II Blocker through Inhibiting Podocyte Injury in Type 2 Diabetic Rats. *J Pharmacol Exp Ther* March 2010 332:1072-1080. [43] Nagase M, Shibata S, Yoshida S, Nagase T, Gotoda T, Fujita T. Podocyte injury

underlies the glomerulopathy of Dahl salt-hypertensive rats and is reversed by

Sub Jung1, Seung-Jae Kwak1, Dong-Ryeol Ryu3, Seung Hyeok Han1, Jung Eun Lee1, Sung Jin Moon1, Dae Suk Han1, and Shin-Wook Kang1. Activation of local aldosterone system within podocytes is involved in apoptosis under diabetic

aldosterone: roles of oxidative stress and sgk1 Hypertension. 2007 Feb;49(2):355-64

chronic kidney disease (CKD): pharmacological effects of mineralocorticoid-

stimulates collagen gene expression andsynthesis via activation of ERK1/2 in rat

stimulates reactive oxygen species production through activation of NADPH

[44] Sun Ha Lee1,\*, Tae-Hyun Yoo1,\*, Bo-Young Nam1,\*, Dong Ki Kim1, Jin Ji Li1,2, Dong-

conditions. *Am J Physiol Renal Physiol* November 2009 297:(5) F1381-F1390; [45] Shibata S, Nagase M, Yoshida S, Kawachi H, Fujita T. Podocytes as the target for

[46] Nishiyama A, Hitomi H, Rahman A, Kiyomoto H. Drug discovery for overcoming

[47] Nagai Y, Miyata K, Sun GP, Rahman M, Kimura S, Miyatake A,et al. Aldosterone

[48] Miyata K, Rahman M, Shokoji T, Nagai Y, Zhang GX, Sun GP, et al. Aldosterone

oxidase in rat mesangial cells. J Am Soc Nephrol. 2005;16:2906–2912.


[21] Sugiyama H, Uchimura I, Odakura T, Maezawa H: Plasma renin and aldosterone in adult-onset diabetics with persistent proteinuria. Jpn J Med 1981 Jul;20(3):194-201 [22] Hene RJ, Boer P, Koomans HA, Mees EJ: Plasma aldosterone concentrations in chronic

[23] Walker WG: Hypertension-related renal injury: a major contributor to end-stage renal

[24] Wakisaka M, Spiro Mj, Spiro RG: Synthesis of type VI collagen by cultured glomerular

[25] Wehling M: Aldosterone specific membrane receptors rapid activation of the sodium-

[26] Funder JW. Mini review: aldosterone and the cardiovascularsystem: genomic and

[27] Chun TY, Pratt JH. Non genomic renal effects of aldosterone. Dependency on NO and

[28] Arima S, Kohagura K, Xu HL, et al. Endothelium-derived nitric oxide modulates vascular action of aldosterone in renal arteriole. Hypertension. 2004;43:352-357. [29] Arima S, Kohagura K, Xu HL, et al. Non genomic vascular action of aldosterone in the

[30] Ponda M, Hostetter T. Aldosterone antagonism in chronic Kidney disease. Clin J Am

[31] Takeda Y, Zhu A, Yoneda T, Usukura M, Takata H, Yamagishi M. Effects of aldosterone

[32] Zhu A, Yoneda T, Demura M, Karashima S, Usukura M, Yamagishi M, Takeda Y. Effect

Dahl salt-sensitive hypertensive rats. *J Hypertens* 2009 April;27(4):800-5. [33] Taira, Masateru1; Toba, Hiroe1 ; Murakami, Masafumi1; Iga, Ikumi1; Serizawa, Ryoko1;

and angiotensin II receptor blockade on cardiac angiotensinogen and angiotensinconverting enzyme 2 expression in Dahl salt-sensitive hypertensive rats. *Am J* 

of mineralocorticoid receptor blockade on the renal renin-angiotensin system in

Murata, Shoko1; Kobara, Miyuki1; Nakata, Tetsuo1. Spironolactone exhibits direct renoprotective effects and inhibits renal renin–angiotensin–aldosterone system in diabetic rats. *European Journal of Pharmacology* . 2008 Jul 28: 589 (1-3) : 264-271 [34] Sang-Youb Han, Cy-Hyun Kim, Han-Seong Kim, Yi-Hwa Jee, Hye-Kyoung Song, Mi-

Hwa Lee, Kum-Hyun Han, Hyoung-Kyu Kim, Young-Sun Kang, Jee-Young Han, Young-Sik Kim, and Dae-Ryong Cha. Spironolactone Prevents Diabetic Nephropathy through an Anti-Inflammatory Mechanism in Type 2 Diabetic Rats

and D R Cha1. Spironolactone ameliorates renal injury and connective tissue growth factor expression in type II diabetic rats. *Kidney International (2006*) 70, 111–

in streptozotocin-induced diabetic rats. *Journal of Renin-Angiotensin-Aldosterone* 

[35] K H Han1, Y S Kang1, S-Y Han2, Y H Jee1, M H Lee1, J Y Han3, H K Kim1, Y S Kim4

[36] Jun Yuan; Ruhan Jia; Yan Bao. Beneficial effects of spironolactone on glomerular injury

120. doi:10.1038/sj.ki.5000438; published online 24 May 2006.

glomerular microcirculation. J Am Soc Nephrol. 2003;14:2255-2263.

nongenomic effects. Endocrinology.2006;147:5564-5567.

genomic actions. Hypertension. 2006;47:636-637.

cells and comparison of its regulation by glucose and other factors with that of type

hydrogen exchanger, and cardiovascular implications. Cardiovasc Res 1995

renal disease. Kidney Int 1982 Jan;21(1):98-101

disease. Am J Kidney Dis 1993 Jul;22:164-73

IV collagen. Diabetes 1994 Jan;43:95-103

Feb;29(2):167-71

Soc Nephrol. 2006;1:668-677.

*Hypertens* 2007 October;20(10):1119-24.

*JASN* May 1, 2006 17: 1362-1372

*System* September 2007 vol. 8 no. 3 118-126


Diabetic Nephropathy: Role of Aldosterone and

Feb;43(2):358-63.

2005; 28:2106-2112.

20:2641-50.

70:2116-2123.

Nephrol. 2006; 1:940-951.

study. Diabet Med. 2004; 21:471-475.

Hypertens. 2006; 24:2285-2292.

factor . JASN 2006 Dec;17(12):3438-46.

nephropathy. Kidney Int. 2005; 68:2829-2836.

blocker. Clin JAm Soc Nephrol. 2006; 1:256-262.

Benefits of Therapy with Aldosterone Receptor Blocker 55

[65] Mejia-Vilet JM, Ramirez V, Cruz C, Uribe N, Gamba G, Bobadilla NA. Renal ischemia-

[66] Aldigier JC, Kanjanbuch T, Ma LJ, Brown NJ, Fogo AB. Regression of existing glomerulosclerosis by inhibition of aldosterone. J Am Soc Nephrol. 2005;16:3306–3314. [67] Nagase M, Yoshida S and Shibat S etal.Enhanced aldosterone signaling in the early

[68] Ehrhart-Bornstein M, Lamounier-Zepter V, Schraven A et al*.* Human adipocytes secrete mineraloc-orticoid-releasing factors. Proc Natl Acad Sci U S A 2003;100:14211-14216. [69] Goodfriend TL, Ball DL, Egan BM, Campbell WB, Nithipatikom K. Epoxy- keto

[70] Schjoedt KJ, Rossing K, Juhl TR, et al. Beneficial impact of spironolactone in diabetic

[71] Rossing K, Schjoedt KJ, Smidt U, et al. Beneficial effects of adding spironolactone to

[72] van den Meiracker AH, Baggen RG, Pauli S, et al. Spironolactone in type 2 diabetic

[73] Sato A, Hyashi K, Sruta T. Antiproteinuric effects of mineralocorticoid receptor blockade in patients with chronic renal disease. Am J Hypertens. 2005; 18:44-49. [74] Mehdi UF, Adams-Huet B, Raskin P, Vega GL and toto RD. Addition of Angiotensin

[75] Chrysostomou A, Pedagogos E, MacGregor L, et al. Double-blind, placebo-controlled

[76] Bianchi S, Bigazzi R, Campese VM. Long-term effects of spironolactone on proteinuria

[77] Epstein M, Buckalew V, Martinez F, et al. Antiproteinuric efficacy of eplerenone,

[78] Epstein M, Williams GH, Weinberger M, et al. Selective aldosterone blockade with

[79] Rachmani R, Slavachevsky I, Amit M, et al. The effect of spironolactone, cilazapril and

[80] Furumatsu Y, NagasawaY, Tomida K, et al. Effect of rennin-angiotensin-aldosterone system

microalbuminuria [abstract]. Am J Hypertens. 2002; 15:24A.

spironolactone. Am J Physiol Renal Physiol. 2007;293:F78–F86.

reperfusion injury is prevented by the mineralocorticoid receptor blocker

nephropathy of rats with metabolic syndrome: possible contribution of fat-derived

Derivative of Linoleic acid stimulates Aldosterone secretion.Hypertension. 2004

recommended antihypertensive treatment in diabetic nephropathy. Diabetes Care.

nephropathy: effects on proteinuria, blood pressure and renal function. J

receptor Blocade or Mineralocorticoid Antagonism to Maximal Angiotensin-Converting Enzyme Inhibition in Diabetic nephropathy. J Am soc Nephrol 2009;

study on the effects of the aldosterone receptor antagonist spironolactone in patients who have persistent proteinuria and are on longterm angiotensinconverting enzyme inhibitory therapy, with or without an angiotensin II receptor

and kidney function in patients with chronic kidney disease. Kidney Int. 2006;

enalapril, and eplerenone/enalapril combination in diabetic hypertensives with

eplerenone reduces albuminuria in patients with type 2 diabetes. Clin J Am Soc

their combination on albuminuria in patients with hypertension and diabetic nephropathy is independent of blood pressure reduction: a randomized controlled

triple blockade on non-diabetic renal disease: addition of an aldosterone blocker,


[49] Terada Y, Kobayashi T, Kuwana H, Tanaka H, Inoshita S, Kuwahara M, et al.

[50] Sun GP, Kohno M, Guo P, Nagai Y, Miyata K, Fan YY, et al. Involvements of Rho-kinase

[51] Nishiyama A, Abe Y. Molecular mechanisms and therapeutic strategies of chronic renal

[52] Kiyomoto H, Rafiq K, Mostofa M, Nishiyama A. Possibleunderlying mechanisms

[53] Fujisawa G, Okada K, Muto S, Fujita N, Itabashi N, Kusano E, et al. Spironolactone

[54] Liu YJ, Nakagawa Y, Toya K, Wang Y, Saegusa H, Nakanishi T,et al. Effects of

[55] Han KH, Kang YS, Han SY, Jee YH, Lee MH, Han JY, et al. Spironolactone ameliorates

[56] Guo C, Martinez-Vasquez D, Mendez GP, Toniolo MF, Yao TM,Oestreicher EM, et al.

[58] Monrad SU, Killen PD, Anderson MR, Bradke A, Kaplan MJ. The role of aldosterone

[59] Rocha R, Stier CT Jr, Kifor I, Ochoa-Maya MR, Rennke HG, Williams GH, et al.

[60] Bobadilla NA, Gamba G. New insights into the pathophysiology of cyclosporine nephrotoxicity: a role of aldosterone. Am J Physiol Renal Physiol. 2007;293:F2–F9. [61] Perez-Rojas J, Blanco JA, Cruz C, Trujillo J, Vaidya VS, Uribe N, et al. Mineralocorticoid

[62] Feria I, Pichardo I, Juarez P, Ramirez V, Gonzalez MA, Uribe N, et al. Therapeutic

[63] Brown NJ, Nakamura S, Ma L, Nakamura I, Donnert E, Freeman M, et al. Aldosterone

[64] Trachtman H, Weiser AC, Valderrama E, Morgado M, Palmer LS. Prevention of renal

types 1 and 2 diabetes mellitus. Endocrinology. 2006;147:5363–5373. [57] Nagase M, Matsui H, Shibata S, Gotoda T, Fujita T. Salt-induced nephropathy in obese

receptor: roleof oxidative stress. Hypertension. 2007;50:877–883.

blockade in murine lupus nephritis. Arthritis Res Ther. 2008;10:R5.

nephrotoxicity. Am J Physiol Renal Physiol. 2007;292:F131–F139.

2005;16:2296–2305.

2006;17: 2193–2201.

2004;66:1493–1502.

2000;57:2064–2071.

Kidney Int.2006;70:111–120.

Endocrinology. 2000;141:3871–78.

Kidney Int. 2003;63:43-52.

Kidney Int. 2000;58:1219–27

Urol. 2004;172:1590–1594.

J Pharmacol Sci.2008:108;399–405.

Aldosterone stimulates proliferation of mesangial cells by activating mitogenactivated protein kinase 1/2, cyclin D1, and cyclin A. J Am Soc Nephrol.

and TGF-beta pathways in aldosterone-induced renal injury. J Am Soc Nephrol.

injury: renoprotective effects of aldosterone blockade. J Pharmacol Sci. 2006;100:9–16.

responsible for aldosterone and mineralocorticoid receptor-dependent renal injury.

prevents early renal injury in streptozotocin induceddiabetic rats. Kidney Int.

spironolactone on systolic blood pressure in experimental diabetic rats. Kidney Int.

renal injury and connective tissue growth factor expression in type II diabetic rats.

Mineralocorticoid receptor antagonist reduces renal injury in rodent models of

spontaneously hypertensive rats via paradoxical activation of the mineralocorticoid

Aldosterone: a mediator of myocardial necrosis and renal arteriopathy.

receptor blockade confers renoprotection in preexisting chronic cyclosporine

benefit of spironolactone in experimental chronic cyclosporine A nephrotoxicity.

modulates plasminogen activator inhibitor- 1 and glomerulosclerosis in vivo.

fibrosis by spironolactone in mice with complete unilateral ureteral obstruction. J


**4** 

Rozina Rani

*Bangladesh* 

**Drug and Diabetic Nephropathy** 

*Chattgram Maa-O-Shishu Hospital Medical College, Agrabad, Chittagong* 

Diabetes mellitus is a group of metabolic disorders characterized by chronic hyperglycemia with disturbances of carbohydrate, fat and protein metabolism resulting from defect in insulin secretion, insulin action, or both. It is the leading cause of heart disease, adult blindness, and amputation of the lower extremities1. Diabetic patient suffer from a number of complications. Of these – hypertension, retinopathy, neuropathy, peripheral vascular disease – are most frequent ones and are responsible for considerable morbidity and mortality. Diabetic nephropathy (DN) is a chronic progressive kidney disease with high morbidity and mortality. There is a gradual loss of renal function ultimately leading to end stage renal disease (ESRD) where life is not sustainable without renal replacement therapy2. The course of DN is characterized by early elevation of arterial blood pressure, increasing albuminuria with gradual decline in glomerular filtration rate (GFR) of 10-12 ml.min-1.year-13,4,5. The degree of albuminuria is closely related to the progression of DN6. Diabetic patients with nephrotic range proteinuria have the fastest decline in GFR7 and the shortest

Proteinuria has been considered an indicator of glomerular disease severity9. The proposed effects of proteinuria on the kidney include increased severity of glomerulosclerosis, tubulointerstitial inflammation, and subsequent fibrosis, thereby contributing to progressive renal function loss. These facts have permitted the establishment of a "proteinuria hypothesis" that consists of three postulates: higher levels of proteinuria predict adverse clinical outcomes; reduction of proteinuria correlates with slowing of renal progression; and

Key to the development of DN is the hyperglycemic state, which has been postulated to mediate its effect in several different ways. First, glucose in sustained high concentrations may be directly toxic to cells, altering cell growth and gene and protein expression and increasing extracellular matrix and growth factor production11. Second, glucose may induce its effects indirectly through the formation of metabolic derivatives such as oxidants and glycation products12,13. Formation of advanced glycation end-products (AGES) may damage cells because of modifications to extracellular matrix proteins and to cellular proteins14.

The renin-angiotensin-aldosterone system (RAAS) is a coordinate cascade of proteins and peptide hormones, the principal effector of which is angiotensin II. In kidney it is regulated via a self-contained renin angiotensin system in a paracrine fashion15. Renin is an enzyme produced by the kidney in response to a number of factors including adrenergic activity (β1-

proteinuria is a surrogate end point and target of clinical interventions10.

**1. Introduction** 

survival time8.

spironolactone, to combination treatment with an angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker. Hypertension Res 2008; 31: 59-67

